title: Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
abstract: This clinical study was performed to evaluate the effects of Duraflo II heparin coated cardiopulmonary bypass equipment on platelet and coagulation/fibrinolysis activation. Twenty-four patients undergoing coronary artery bypass grafting were assigned to two groups using either heparin coated (Duraflo group, n = 13) or uncoated equipment (control group, n = 11). In the Duraflo group, the cardiotomy reservoir was also coated with heparin. Standard systemic heparinization was performed in both groups. There were no significant differences in activated clotting times or plasma free hemoglobin concentrations between the two groups. Platelet loss and platelet activation, as measured by increases in plasma beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4), in the Duraflo group (beta-TG:237 +/- 143 ng/ml, PF4:167 +/- 104 ng/ml at the end of cardiopulmonary bypass) were less than those in the control group (beta-TG:373 +/- 131 ng/ml, PF4:295 +/- 131 ng/ml at the end of cardiopulmonary bypass). No significant differences were found in thrombin-antithrombin III complex levels or alpha 2 plasmin inhibitor-plasmin complex levels between the groups. Therefore, the use of Duraflo II heparin coated equipment with a heparin coated cardiotomy reservoir suppressed platelet activation.
authors.affiliation: Third Department of Surgery, Iwate Medical University, School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakajima
authors.forename: S
authors.initials: S
authors.lastname: Osawa
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
authors.forename: H
authors.initials: H
authors.lastname: Izumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Yagi
authors.forename: K
authors.initials: K
authors.lastname: Kawazoe
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D000990:Antithrombin III / Q000378:metabolism; D001672:Biocompatible Materials / Q000378:metabolism*; D001792:Blood Platelets / Q000502:physiology*; D002315:Cardiopulmonary Bypass / Q000592:standards*; D001026:Coronary Artery Bypass; D005342:Fibrinolysis / Q000502:physiology*; D006493:Heparin / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects* / Q000502:physiology; D010978:Platelet Factor 4 / Q000378:metabolism; D011446:Prospective Studies; D013917:Thrombin / Q000378:metabolism; D001620:beta-Thromboglobulin / Q000378:metabolism
chemical_list: D001672:Biocompatible Materials; D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D000990:Antithrombin III; D006493:Heparin; D013917:Thrombin